Recently, fibroblast growth factor 23 (FGF23) has gained broad attention as a disease biomarker in CKD, since elevated FGF23 plasma concentrations are observed in an early stage of CKD, and increase proportionally with renal function decline [93]. This evidence concerns the gene FGF23 and chronic kidney disease.